Targeted cancer gene therapy: The flexibility of adenoviral gene therapy vectors

M. G. Rots, D. T. Curiel, W. R. Gerritsen, H. J. Haisma

Research output: Contribution to journalArticle

Abstract

Recombinant adenoviral vectors are promising reagents for therapeutic interventions in humans, including gene therapy for biologically complex diseases like cancer and cardiovascular diseases. In this regard, the major advantage of adenoviral vectors is their superior in vivo gene transfer efficiency on a wide spectrum of both dividing and non-dividing cell types. However, this broad tropism at the same time represents an important limitation for their use in therapeutic applications where specific gene transfer is required. This limitation may be overcome by using targeting approaches. In this regard, targeting may be achieved at three levels: transductional targeting, translational targeting and targeting of the expressed transgene. Here we describe our research efforts towards cancer specific gene therapy using these different targeting approaches. The results show that targeting of adenoviral vectors may be achieved using cancer specific cell surface molecules for transductional and transgene targeting or cancer specific promoters for transcriptional targeting. Combinations of these targeting approaches should result in optimized cancer specific gene therapy.

Original languageEnglish (US)
Pages (from-to)159-165
Number of pages7
JournalJournal of Controlled Release
Volume87
Issue number1-3
DOIs
StatePublished - Feb 21 2003
Externally publishedYes

Fingerprint

Neoplasm Genes
Genetic Therapy
Transgenes
Neoplasms
Tropism
Therapeutic Uses
Genes
Cardiovascular Diseases
Research
Therapeutics

Keywords

  • Adenoviral
  • CRAd
  • Gene therapy
  • Transductional retargeting
  • Tumor specific promoter

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Targeted cancer gene therapy : The flexibility of adenoviral gene therapy vectors. / Rots, M. G.; Curiel, D. T.; Gerritsen, W. R.; Haisma, H. J.

In: Journal of Controlled Release, Vol. 87, No. 1-3, 21.02.2003, p. 159-165.

Research output: Contribution to journalArticle

Rots, M. G. ; Curiel, D. T. ; Gerritsen, W. R. ; Haisma, H. J. / Targeted cancer gene therapy : The flexibility of adenoviral gene therapy vectors. In: Journal of Controlled Release. 2003 ; Vol. 87, No. 1-3. pp. 159-165.
@article{1e14d7d0493b495a91572e5696e4c0b6,
title = "Targeted cancer gene therapy: The flexibility of adenoviral gene therapy vectors",
abstract = "Recombinant adenoviral vectors are promising reagents for therapeutic interventions in humans, including gene therapy for biologically complex diseases like cancer and cardiovascular diseases. In this regard, the major advantage of adenoviral vectors is their superior in vivo gene transfer efficiency on a wide spectrum of both dividing and non-dividing cell types. However, this broad tropism at the same time represents an important limitation for their use in therapeutic applications where specific gene transfer is required. This limitation may be overcome by using targeting approaches. In this regard, targeting may be achieved at three levels: transductional targeting, translational targeting and targeting of the expressed transgene. Here we describe our research efforts towards cancer specific gene therapy using these different targeting approaches. The results show that targeting of adenoviral vectors may be achieved using cancer specific cell surface molecules for transductional and transgene targeting or cancer specific promoters for transcriptional targeting. Combinations of these targeting approaches should result in optimized cancer specific gene therapy.",
keywords = "Adenoviral, CRAd, Gene therapy, Transductional retargeting, Tumor specific promoter",
author = "Rots, {M. G.} and Curiel, {D. T.} and Gerritsen, {W. R.} and Haisma, {H. J.}",
year = "2003",
month = "2",
day = "21",
doi = "10.1016/S0168-3659(02)00360-7",
language = "English (US)",
volume = "87",
pages = "159--165",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - Targeted cancer gene therapy

T2 - The flexibility of adenoviral gene therapy vectors

AU - Rots, M. G.

AU - Curiel, D. T.

AU - Gerritsen, W. R.

AU - Haisma, H. J.

PY - 2003/2/21

Y1 - 2003/2/21

N2 - Recombinant adenoviral vectors are promising reagents for therapeutic interventions in humans, including gene therapy for biologically complex diseases like cancer and cardiovascular diseases. In this regard, the major advantage of adenoviral vectors is their superior in vivo gene transfer efficiency on a wide spectrum of both dividing and non-dividing cell types. However, this broad tropism at the same time represents an important limitation for their use in therapeutic applications where specific gene transfer is required. This limitation may be overcome by using targeting approaches. In this regard, targeting may be achieved at three levels: transductional targeting, translational targeting and targeting of the expressed transgene. Here we describe our research efforts towards cancer specific gene therapy using these different targeting approaches. The results show that targeting of adenoviral vectors may be achieved using cancer specific cell surface molecules for transductional and transgene targeting or cancer specific promoters for transcriptional targeting. Combinations of these targeting approaches should result in optimized cancer specific gene therapy.

AB - Recombinant adenoviral vectors are promising reagents for therapeutic interventions in humans, including gene therapy for biologically complex diseases like cancer and cardiovascular diseases. In this regard, the major advantage of adenoviral vectors is their superior in vivo gene transfer efficiency on a wide spectrum of both dividing and non-dividing cell types. However, this broad tropism at the same time represents an important limitation for their use in therapeutic applications where specific gene transfer is required. This limitation may be overcome by using targeting approaches. In this regard, targeting may be achieved at three levels: transductional targeting, translational targeting and targeting of the expressed transgene. Here we describe our research efforts towards cancer specific gene therapy using these different targeting approaches. The results show that targeting of adenoviral vectors may be achieved using cancer specific cell surface molecules for transductional and transgene targeting or cancer specific promoters for transcriptional targeting. Combinations of these targeting approaches should result in optimized cancer specific gene therapy.

KW - Adenoviral

KW - CRAd

KW - Gene therapy

KW - Transductional retargeting

KW - Tumor specific promoter

UR - http://www.scopus.com/inward/record.url?scp=0037458826&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037458826&partnerID=8YFLogxK

U2 - 10.1016/S0168-3659(02)00360-7

DO - 10.1016/S0168-3659(02)00360-7

M3 - Article

C2 - 12618032

AN - SCOPUS:0037458826

VL - 87

SP - 159

EP - 165

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

IS - 1-3

ER -